


Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Mexico 2019 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Mexico and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board

Liliana Joachín Rodríguez
Quality and RA Director

Sergio Valentinotti
Life Science Director

Cecilia Bravo
CEO

Carlos Bertoncini
Innovation Project Director

Ector Jaime Ramirez
Diputado Federal LXIV Legislatura y secretario de la comisión de salud

Leah Christl
Executive Director, Global Regulatory and R&D Policy, JAPAC Lead and Global Biosimilars

Emilio Medina
Scientific Technical Director

Marielle Pascual Quintero
Expert in Regulatory Matters and Associate Professor

Nestor Lago
Medical Director

Vivian Lee
Director of Medical Affairs

Leonidas Unzueta
Medical Director

Nicolas Linares
VP & GM Mexico and Central America

Laura Palomares
Researcher and Professor

William Rodriguez Limas
Director of Biotechnology Development

Maria Fernanda Thees
Health Regulation and Surveillance Specialist

Nestor Perez
Operations Director

Oscar Gamiz
Marketing Head PS Latam

Eduardo Cioppi
Regional Director - Latin America

Lori Daane
Director of Scientific Affairs

Ricardo Castro
VP of Bioprocessing
Biosimilars: Scientific evidence and its impact on patients
Current Development and Regulatory Challenges in Mexico
Nancy Huertas
Keralty, Colombia
Global Director of Pharmaceutical Affairs
Jorge García
BIOREDCOL, Colombia
President
EMA Experience with Biosimilar Approvals and Cross Border Utilisation
Regulatory Harmonisation Activities by Argentina, Brazil and Mexico
Pharmacovigilance. Signal Management. Safety Surveillance. Risk communication.
New Commercial Agreements in the region
Proposal to Revise the Regulation of Biosimilars in Mexico

Sponsors
Photo Gallery
